GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vertex Pharmaceuticals Incorporated (VRTX) [hlAlert]

Rating:
Buy VRTX
up 497.09 %

Vertex Pharmaceuticals Incorporated (VRTX) upgraded to Buy by Merriman Curhan Ford

Posted on: Thursday,  Oct 30, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on 10/30/2008, when the stock price was $22.40.
Since then, Vertex Pharmaceuticals Incorporated has gained 497.10% as of 12/01/2015's recent price of $133.75.
If you would have followed this Merriman Curhan Ford's recommendation on VRTX, you would have gained 497.09% of your investment in 2588 days.

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2008 8:25 AM Buy
None
22.40
as of 12/24/2008
1 Week down  -3.53 %
1 Month down  -7.33 %
3 Months down  -38.59 %
1 YTD down  -10.99 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/11/2008 8:25 AM Hold
None
14.82

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy